Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics, Agensys to jointly develop second ADC
ASG-22ME is an ADC composed of a fully human antibody directed to Nectin-4, an antigen expressed in multiple cancers including bladder, breast, lung and pancreatic cancers. ASG-5ME currently
ASG-22ME is an ADC composed of a fully human antibody directed to Nectin-4, an antigen expressed in multiple cancers including bladder, breast, lung and pancreatic cancers. ASG-5ME currently
Silenor is a low-dose (3 mg and 6 mg) oral tablet formulation of doxepin, indicated to treat insomnia characterized by difficulties with sleep maintenance. As per the terms
So far, the company recruited around 500 patients in the trial, whose primary endpoint is overall survival. Merck Serono Oncology Global Clinical Development Unit senior vice president Oliver
Galapagos expects to recruit around 36 subjects in the trial to investigate the safety, efficacy, tolerability and the pharmacokinetics of GLPG0634 in treating RA. The primary efficacy endpoint
As per the agreement, Hovione and PSI will bring their spray-drying based sloid solution technologies to maximize the bioavailability of BCS Class II active pharmaceutical ingredients. Development will
In a Phase IIb open-label trial evaluating infants at 2, 4, 6 months or at 2, 3, 4 months with or without routine vaccines, Bexsero demonstrated that the
Previously, DMC asked Merck to terminate patient recruitment as the study failed to meet the formal futility criteria. The decision was based on the data which showed overall
TargetRx, through its AdvantageBuilder database of more than 300 million questions answered by over 80,000 physicians, has identified 11 attributes, or Y-Factors, that motivate physicians to prescribe. The
With this partnership, LSK can implement and support Medidata Rave across all trial phases, sizes and locations and offer sponsors and investigators the ability to reduce delays and
ANVISA provides regulatory approval for drugs and other products seeking to enter the large and growing Brazilian market. In addition to ANVISA certification, Celerion’s Belfast facility has also